tiprankstipranks
ERYTECH PHARMA (GB:0QSS)
LSE:0QSS
Holding GB:0QSS?
Track your performance easily

ERYTECH PHARMA (0QSS) Share Price & Analysis

0 Followers

0QSS Stock Chart & Stats


Financials

Annual

0QSS FAQ

What was ERYTECH PHARMA’s price range in the past 12 months?
ERYTECH PHARMA lowest share price was €1.57 and its highest was €4.46 in the past 12 months.
    What is ERYTECH PHARMA’s market cap?
    Currently, no data Available
    When is ERYTECH PHARMA’s upcoming earnings report date?
    ERYTECH PHARMA’s upcoming earnings report date is Mar 19, 2025 which is in 97 days.
      How were ERYTECH PHARMA’s earnings last quarter?
      Currently, no data Available
      Is ERYTECH PHARMA overvalued?
      According to Wall Street analysts ERYTECH PHARMA’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does ERYTECH PHARMA pay dividends?
        ERYTECH PHARMA does not currently pay dividends.
        What is ERYTECH PHARMA’s EPS estimate?
        ERYTECH PHARMA’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does ERYTECH PHARMA have?
        ERYTECH PHARMA has 10,013,719 shares outstanding.
          What happened to ERYTECH PHARMA’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of ERYTECH PHARMA?
          Currently, no hedge funds are holding shares in GB:0QSS
          ---

          ERYTECH PHARMA Stock Smart Score

          10
          Unlock Smart Score
          1
          2
          3
          4
          5
          6
          7
          8
          9
          10

          Fundamentals

          Return on Equity
          -84.18%
          Trailing 12-Months
          Asset Growth
          -40.32%
          Trailing 12-Months

          Company Description

          ERYTECH PHARMA

          Erytech Pharma SA is a clinical-stage biopharmaceutical company. It is engaged in conducting activities in research and development in the fields of treatment for acute leukemia and other orphan diseases. The approach by the firm consists of acting on the tumor's environment and starving it so that the cancerous cells no longer have access to the growth factors that are necessary to live and proliferate. Most of the activities of the group are located in France. The company ERYCAPS proprietary platform to encapsulate active drug substances inside red blood cells using reversible hypotonic and hypertonic osmotic stress. The company's geographical segments are France and the United States, out of which the United States contributes to the majority of the revenue.
          ---
          Popular Stocks
          ---
          What am I Missing?
          Make informed decisions based on Top Analysts' activity
          Know what industry insiders are buying
          Get actionable alerts from top Wall Street Analysts
          Find out before anyone else which stock is going to shoot up
          Get powerful stock screeners & detailed portfolio analysis